• Without comparative effectiveness research (CER), payers and Centers for Medicare & Medicaid Services (CMS) must make decisions based on the best evidence available, which often lacks headto-head data comparison, uses surrogate endpoints, and excludes the specific elderly or disabled population that Medicare covers.
• There is a common misperception that the CMS is not allowed to use CER data when making decisions.
What is already known about this subject
• Contrary to a common misperception, CMS is allowed to use CER data when making coverage decisions, albeit with some limitations. • CER could be used when creating patient decision aids, establishing value-based insurance design, and in coding (determining whether there is enough of a significant therapeutic distinction for a particular product to assign it a new code).
• CMS could use CER data in pricing decisions-specifically in the area of least-costly alternative (or reference pricing).
What this article adds
• Greater use of Coverage with Evidence Development is a mechanism to stimulate the generation of relevant CER for the Medicare program.
• Some possible impediments to integrating more CER into CMS decisions may be a lack of training in how to utilize observational data, as well as an inadequate number of epidemiologists on staff who can manage the future increase in volume of CER data. • This article makes arguments for why CMS should have a voice in setting priorities for research funded by the Patient-Centered Outcomes Research Institute (PCORI), so that the resulting research will be meaningful to CMS decision makers.
What this article adds (continued)
area of decision making around prostate cancer treatments provides a good example. Prostate cancer is the leading cause of cancer and the second leading cause of mortality among men. 4 While there are many alternatives for treating prostate cancer, there is a lack of robust evidence about which treatments work best at what stage of the disease. 5 In 2002, CMS covered intensity modulated radiation therapy (IMRT) on the basis of limited information about its performance relative to brachytherapy (which was the standard in use at the time). At the time, the cost of IMRT was about double that of brachytherapy. 6 Within a few years, roughly one-third of beneficiaries were using IMRT, and expenditures were well over a billion dollars for that particular technology. 7 More recently, proton beam therapy was introduced, and Medicare contractors made the decision to cover it. This essentially doubled Medicare expenditures again for a course of radiation therapy for prostate cancer, but still without good evidence that it improves the quality of care over IMRT or even over brachytherapy. We still do not know which therapies are more effective for which patients and which stages of prostate cancer, but treatment costs for this condition continue to escalate. Unfortunately for prostate cancer patients, these types of decisions not only affect their out-of-pocket obligations, but also could result in exposing them to undue toxicities and risk.
A defining feature of CER that makes it fundamentally different from the way clinical research has been done in the past is its purpose. According to the Institute of Medicine (IOM), "The purpose of CER is to assist consumers, clinicians, purchasers, and policy makers to make informed decisions that will improve health care at both the individual and population levels." 8 To this effect, CER provides unique opportunities for CMS to improve its policies to ensure medical services are used more appropriately.
Can CMS Legally Use CER?
There is a common misperception that CMS is not allowed to use CER results when making decisions. The truth is that CMS is allowed to use CER data, albeit with some limitations. The limitations imposed on CMS's use of CER are fairly modest. CMS must use an iterative and transparent process, and they cannot use CER as a sole source of information. 9 The Patient Protection and Affordable Care Act (ACA) 9 of 2010 includes specific limitations on Medicare's use of CER. 10 CMS can't use it in a manner that treats the life extension of the elderly, disabled, or terminally ill differently than others, and they can't use it to preclude or discourage choices between extending life or risk of disability. 10 Additionally, CMS can't include mandates for coverage or payment, cannot use cost per quality adjusted life years threshold to determine coverage or payment and must use evidence only as part of a larger process. 10 In fact, these limitations reflect the way CMS already makes coverage decisions, and these limitations do not fundamentally change CMS's current processes.
The larger question is how these limitations from the ACA affect CMS's ability to use costs. The Patient-Centered Outcomes Research Institute (PCORI), a public/private entity charged with identifying research priorities, establishing an agenda, and fundLooking at CER from Medicare's Perspective ing future CER studies, created under the ACA, 9 cannot fund research or advocate for a threshold for quality-adjusted life years (QALYs). In addition, the ACA imposed a restriction that the Secretary of Health and Human Services, acting for the Medicare program, could not use a "threshold" for QALYs in their coverage determinations. CMS has gone on record in guidance documents stating that they don't use cost or cost-effectiveness in their decision making. This restriction against using a threshold of QALYs is not a new limitation for CMS, but it is now incorporated into statute.
Another important aspect of the ACA is that it explicitly allows CMS to use differential copayments based on cost, which could open the potential of using value-based insurance design within the CMS program.
CMS's Obligation to CER: Making Data Available for Research
In recent years, significant federal funds have been expended in building an infrastructure to support CER, such as registries and claims databases. One of the legislative requirements is that CMS must make its data available for PCORI-sponsored research. Although CMS data have been available for a long time, the data have been relatively difficult to obtain. This new requirement may facilitate researcher access.
To that end, one of the major investments has been the development of the Multi-Payer Claims Database (MPCD). 11 The database combines Medicare data, including the institutional claims in Part A, outpatient claims from Part B, and the drug data from Part D, with claims data from private insurers. This potentially will deliver a much more robust observational data set for doing CER. Currently, 1 private payer is contributing claims data and hopefully more insurers will contribute data over time. Medicare data provide a rich resource for CER.
Using existing Medicare data, as with other claims data, is challenging. It is not possible to determine factors that contribute to treatment decisions, patients are not randomly assigned to treatment, and selection bias is an issue. These could be resolved if beneficiaries were randomly assigned to plans with different formularies based on factors such as low income subsidies. 12 However, much work remains in determining how to implement this requirement. Some of the outstanding questions include: How should a public/private partnership like this be sustained? Should there be benefits to the participants who add their private claims to the database, and if so, what type of benefits? Who will own the data? And how should the data be made available to researchers? Another important question is whether these data will be linkable to clinically rich information from randomized controlled trials or electronic health records, which could potentially make this a much more powerful and robust source.
Another outstanding question is whether this investment will result in observational data becoming more acceptable for coverage decision making. Currently, observational data are seldom used for making Medicare national coverage determinations. Some possible impediments to integrating observational data into coverage decisions may be a strong existing bias that randomized controlled trials (RCTs) are the only acceptable method for answering questions about relative effectiveness and an inadequate number of epidemiologists on staff who understand how to utilize observational data.
A Disconnect: The Lack of a Voice in Setting Priorities for CER Investment CER will be credible, timely, and relevant to Medicare beneficiaries only if CMS becomes a more active participant in defining research priorities. The agency needs comparative studies that address issues specific to the elderly, chronically ill, and disabled populations that it serves. When comparing the top 20 priorities established by CMS in 2007 with those established by the IOM and those established by the National Institutes of Health (NIH) for NIH Challenge Grants, 13 there are some notable differences (Table 1) . Specifically, CMS was interested in looking at the impact of expensive cancer drugs, the use of reperfusion drugs for stroke prevention, and erythropoietin-stimulating agents and their use in cancer patients.
The Medicare program, either by design or by default, does not currently have an active voice in establishing priorities for CER investment. Although the legislation allocated space on PCORI's governing board for 2 federal or state representatives, 9 CMS is not represented. If CMS doesn't have a seat at the table in PCORI and if there's no effective mechanism for CMS to influence the types of studies being done, potentially there may be major gaps in the type of relevant and critical information that they need.
The Future of CER in the Medicare Program CER has the potential for broad usage throughout the Medicare program. Not only could the results be used to inform coverage decisions, but they could also be used to support patient decision aids and assist in coding decisions (determining whether there is enough of a significant therapeutic distinction for a particular product to assign it a new code). In addition, and perhaps even more importantly for CMS, CER data could be used in pricing-specifically in the area of developing policies for value-based insurance design and least-costly alternative pricing (or reference pricing). Through least-costly alternative pricing, Medicare contractors have the discretion to use relative costs in setting payments if there are 2 alternative items with equal efficacy. This has been used primarily to set payments for durable medical equipment. While a recent legal ruling has restricted use of this policy for drugs, this approach could help promote the generation of better CER for Medicare decisions. 14 For example, in the prostate cancer case, if research couldn't demonstrate a significant clinical difference between proton beam therapy and intensity modulated radiation therapy, then CMS could pay the same for those treatments rather than paying different amounts for each. Pearson and Bach suggest a framework where new technology would be paid for at a higher rate than existing technology for 3 years. At the end of the third year, cost for the new technology would be reduced to the existing technology cost unless the new technology demonstrated clinical advantages to justify the additional cost. 10 Another policy tool the agency has to help promote the development of CER is Coverage with Evidence Development (CED), also referred to as conditional coverage. CED links reimbursement to the requirement for prospective data collection. This policy tool allows CMS to help drive clinical research to ensure it is more relevant to its needs, such as ensuring that the 
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